Psychedelic Policy Briefing 8.21.26
Resilient Pharmaceuticals reportedly resubmitted its New Drug Application (NDA) for MDMA-assisted therapy for PTSD to the FDA. This resubmission initiates a new review cycle, which will operate under the agency's recently finalized psychedelic clinical trial guidance.
By Jack Gorsline · Published August 26, 2026
Sourced from lucid.news, published August 21, 2026. Cite the original publication, not this page, for the reporting itself.
Resilient Pharmaceuticals reportedly resubmitted its New Drug Application (NDA) for MDMA-assisted therapy for PTSD to the FDA. This resubmission initiates a new review cycle, which will operate under the agency's recently finalized psychedelic clinical trial guidance.